The company has filed a patent on its StemVacs dendritic cell therapy for boosting COVID-19 immunity, it said. The patent describes how StemVacs prompts the body to boost activity of "natural killer" immunological cells, which have been shown to inhibit SARS-CoV-2.

StemVacs is being developed both as standalone immunotherapy as well as an adjuvant product to improve the efficacy of stimulators of the adaptive immune responses, according to Therapeutic Solutions. The ability to supercharge dendritic cells provides a unique virology approach to fighting COVID-19.

FDA researchers describe lessons learned from COVID-19 immunology
Key immunological factors underlying the clinical stages of COVID-19 that could be targeted by therapeutic drugs were outlined in a review by U.S. Food...

City of Hope sponsors COVID-19 research
City of Hope released details of multiple COVID-19 research projects, including the development of two potential vaccines, new therapies, and better screening...

Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...